will have five legislative days to submit a question to you for additional materials for the record and ask that you respond to those and it will be in your interest to respond to those promptly. >> we will get to them as quickly as we can. >> the hearing is adjourned. [inaudible conversations]

[inaudible conversations] [inaudible conversations] [inaudible conversations]

[inaudible conversations] [inaudible conversations] >> the smithsonian national museum of african-american history and culture opens its doors to the public for the first time saturday and c-span will be live from the national mall for the outdoor dedication ceremony. speakers include president obama and museum director, also in attendance will be michelle obama, george w. bush and mrs. laura bush, supreme court chief

justice john roberts, congressman john lewis and smithsonian secretary david fortin. watch the opening ceremony for the smithsonian national museum of african-american history and culture saturday morning at 10 am eastern on c-span, c-span radio apps and c-span.org. >> defense secretary ash carter in joint chiefs chairman joseph dunford are on capitol hill this morning briefing senators on national security and operations against isis live at 9:30 eastern on c-span3. you can watch online or listen on the c-span radio apps. we are at a house hearing on management of the national park service on c-span3. >> mylan ceo heather bresch answered questions about a 500% price increase over 7 years on mylan's injection known as the

epipen. we will show you the first part of the government reform committee. >> committee on oversight will come to order. without objection the chair is authorized to declare recess at any time. an important hearing today reviewing the price of epipen. anaphylactic shock will kill 1500 people a year. 1400 people and i, they don't get the appropriate dose of epinephrine. one of the ways you can stop your child or loved one from dying or going into shock. this is a drug, generic drug that has been around for 100 years and it works, it is a good product. people, parents, they need it. it is not optional for somebody

who has severe allergic reactions to a variety of things. what we are here to discuss, to drive into the depth of individual drug pricing, is not something i said out to do. but it doesn't take long to talk to parents or talk to people who are afraid that if this epipen is not within arm's reach when their young child suddenly needs it, you don't have to talk to somebody very long to figure out they have to have this. it is not optional. it has been on the market for 100 years, costs roughly a

dollar. but the price of this has gone from roughly $99 for one to more than $600 for two in a very short amount of time. you see year over year prices jump $100 here and there, a product that is not available on insurance plans, not mandated like other things like obamacare mandated so suddenly you have people who can't afford what is a one year dose, and expiration date of the year. you get two of them, some have 10 of them, the car, the backpack and we are talking $600 to the consumer that have two of those so we have a lot of

questions. mylan as best i can tell from afar had looked at it and has done a lot of good for a lot of good products 635 products, this generates 10%. 10% of the revenue in this one product. they are here to tell us they make $50 in profit which i find a little hard to believe. that is why it is important for the ceo to talk to us. telling us the middleman makes more than we do, we get less than half of that revenue goes to mylan but here is what doesn't add up. i am a person who believes in profit and profit motivation, you have five executives in five

years that earned nearly $300 million. this is by all accounts as best i can tell one of the biggest revenue drivers. used to have a competitor, in 2010, when that other market left the market the product price moved, it went up. another example of a life-saving drug you have to have, if you don't have it you are going to die and there is no competition which brings us to why we -- one of my concerns based on the sole economics of it, basic economics, you have a generic product that has been on the market for 100 years and you see this massive rise in the cost of the price to the consumer.

that would signal to entrepreneurs there is an ability to make a profit. when you understand the cost of goods is only one dollar, the delivery vehicle which is unique and innovative there is a cost to that too but when it sells for $600 there is room for some profit but new market interests are not able to submit an application it is through the fda, you have in this case mylan, raised the price to bring an exorbitant amount of profit with no competition. my brother said why are you trying to get into the business of a private entity? the market forces aren't at work. competition cannot be in their. competition would be good. it would help drive down the price. the last thing i would mention

along the way, suddenly feeling the pressure, mylan offered a generic version and cut the price in half that does beg the question, what is happening with the other $300? driving the price down is great but congress shouldn't be micromanaging that but i do think this is worth exploring because different drug earlier this year we did hearings, it is happening in others, not as egregious or rapid rise, but i find this to be so extreme, they have to have it, there is no

competition, not covered under insurance, driving exorbitant profits and that is why myself and mister cummings are united in trying to address this, understand it better, we don't have the same solutions but to my original premise, parents don't have a choice. your child, loved one has to have this. it better be there. we want to offer some understanding as we go through that. every day more people are going to die. now recognize the gentleman from maryland. >> mister chairman, thank you for holding this hearing.

this issue of skyrocketing prices of drugs has been one of my top priorities for several years. this hearing is critical because yet another drug company, mylan, has jacked up the price of a life-saving product for no discernible reason. i was not impressed by your testimony. they raised the prices, the reason being i believe to get filthy rich at the expense of our constituents. at the expense of our constituents. now your epipen, the epipen has been around for decades was introduced in 1988.

the active ingredient has been around even longer. what changed? what changed? what changed? mylan acquired epipen in 2007. then used a simple but corrupt business model that other drug companies have repeatedly used, we have seen it over and over and over again, find an old cheap drug that has virtually no competition and raise the price over and over and over again as high as you can, that is what martin's grill he did and what

valiant's ceo did earlier this year with absolutely no remorse, none. in mylan's case they had a virtual monopoly over the market, decided to take advantage. used to cause about $100 for two epipens, now costs more than $600. to understand why mylan raised these prices so dramatically we need to understand how much money they are making off of this drug. according to documents obtained by the committee, epipen generated $184 million in revenue. $184 million. in 2016 listen to this, mylan

expect this number to go up to more than $1.1 billion. that is more than a fivefold increase over ten years. what else changed since 2007? the mylan became mylan -- the epipen became mylan's first billion dollars drug, $4 million in net sales revenue, one drug over the last decade and rebate the discounts. my my my. also engaged in a massive marketing campaign. according to information obtained by the committee mylan spent $100 million for advertising and marketing for epipen last year alone. then came the price increases.

when mylan acquired epipen in 2007 the cost of two epipens was about $100. in 2012 they raised the price to $218,000 and in 2014 they raised it again. see the pattern? they raised it again to $350. in 2015 they were on a roll, $260, and now it is $608. the price of epipen shot up exponentially. and fellow executives at mylan. and $2.45 million for financial

reports. the compensation has soared to $18 million, a 50% increase. mylan's chairman got even more, $22.5 million in 2014 alone. after the public backlash the most recent price increase would expand assistance programs. this is the same playbook other companies use, price increases finally spark outrage, the patient assistance program and make as much money as you can along the way.

that is what martin should really did and what mylan is doing. here is the bottom line. i begged martin to use his influence to lower their prices. i pleaded with executives to lower their prices. i called on mylan to reverse its strate strategy. but they all refused. talked about discounts and coupons and rebates even with withering bipartisan pressure from congress and desperate outcries in the american people, and by the way the american people who sent these people to represent them every single person up here has somebody affected by this. they never never lowered the

prices. i am concerned this is a rope a dope strategy, they hold -- the industry will face. then they go right ahead and keep on raising their prices. just go in, congress will be upset with you but you come out and we will keep raising prices, keep doing it. after mylan takes our country they will fly back to their mansion in their private jets and laugh all the way to the bank while constituents suffer, file for bankruptcy and watch their children get sicker or die. that is what we are dealing with today. yesterday someone asked if i wanted the head of mylan to apologize. i had to think about that for a

minute. it would be more appropriate, it would be nice if she did but that will not cause mylan to treat my constituents fairly and bring down the price to where it should be. we need solutions, i agree, mister chairman and this is a bipartisan effort, time for congress to act. we will hold today's hearing like we held our previous hearings. we had martin shkreli before us, he said something that i think about over and over and over again. as soon as he got out you know what he called it? in the seals -- in basiles, he knew they would go back and do the same thing over and over

again. he took the fifth and the prices kept on going up. so all of our colleagues, this is our moment. is there something we do in a bipartisan way? this is it. i watched the chairman in an interview and i could tell he and i were getting emotional. you know why? we were thinking of our children, children who may have some kind of spell and need to breathe. i hope after the hearing is over that you don't go back to the champagne, we go on to life as it was. our constituents deserve better.

i yield back. >> we hold the record open. we now recognize our panel of witnesses, please welcome doctor doug throckmorton, deputy director for drug evaluation and research of the fda and heather bresch, chief executive officer of mylan. we welcome you both, pursuant to committee rules all witnesses are to be sworn before they testify. please rise and raise your right hand. do you solemnly swear or affirm the testimony you are about to give will be the truth, the whole truth and nothing but the truth? thank you, you may be seated. let the record reflect both witnesses answered in the affirmative we would like to recognize you for five minutes, if you want to go a bit longer

that is fine, but we want to maximize the time, your entire statement will be entered into the record, you are recognized for five minutes. >> ranking member cummings. >> bring the microphone up close, bring it uncomfortably close. >> chairman chaffetz, ranking member chaffetz, i am doctor doug throckmorton, deputy director of regulatory programs, the center for drug evaluation at the fda. thank you for the opportunity to appear before you to discuss fda's role in assuring the safety and adequacy and availability of epinephrine auto injectors. epinephrine auto injectors where the most widely used and recognizable product, critically

important and potentially life-saving for patients who suffer severe allergic reactions of anaphylaxis. when a patient requires this medication, seconds count and it must work every time. to ensure this it is critical for the medication and the device that delivers it perform as designed, we are aware of the recent spikes in the price of epipen. i am personally aware of it as my son carries and epipen -- epinephrine autoinjector for his allergies. fda does not have a regulatory role in the pricing of drug products, we do play a critical role in ensuring people have access to beneficial medicines. a generic version is approved to marketplace competition and provide additional options. with this role in mind fda is working to support the timely scientific development of new

epinephrine autoinjector products. epipen is not the only product approved to treat anaphylaxis in an emergency. four products to treat anaphylaxis two of which are on the market. supporting new epinephrine autoinjector developments the fda cannot approve a product which we haven't received an application which is why we are doing all we can to support manufacturers as they work to develop innovative new product including new epinephrine autoinjector products and bring them to the market faster. in 2013 the agency provided technical information to divine interest autoinjector's. we release draft guidance on how to determine whether these devices can be used effectively

by patients. these can help development by providing a clear roadmap to reduce uncertainty that can slow development. we recognize the importance of generic drugs in the united states and working in this area to support their development. as part of the larger work to improve the review and development of generic drugs fda's office of generic drugs has a prioritization and expedited review policy that allows certain products to get priority including products that are called, quote, first generics. to close, thank you for your interest in this topic related to safety efficacy and availability of epinephrine auto injectors, and working hard to fulfill the role. one part of the mission is to in a sure medical products are safe and effective and can be used as needed as part of the mission, fda is playing an important role in advancing public health by

helping speed innovation that promotes wider availability of these products which for complex medical products like epinephrine autoinjector this means providing a roadmap to developers seeking to market new products and working with them whenever possible in support of product development. these efforts coupled with the work of other groups will help assure access to these dedications. medications. >> miss bresch, you are recognized. >> good afternoon, chairman chaffetz and ranking member cummings and numbers of the committee. i am heather bresch the ceo of mylan and i appreciate the chance to be with you today. before i answer your questions i would like to share a little information on my background at

mylan and tell you what we have done to address concerns about the price and availability of epipens. i grew up in a small town in west virginia in a family with a strong work ethic. i joined mylan as an entry-level clerk with basic and ministry of tasks in the basement of the company's manufacturing facility and worked through 15 roles in the company until i reached my current position. when i started with mylan our sales were 100 million with 500 employees and today our sales are in excess of 11 billion, more than 40,000 employees. one in 13 us prescriptions is filled with one of mylan's medications. i would like to highlight two fact about mylan. we are not the kind of pharmaceutical company that offers only a handful of products. we are the exact opposite. over the last 55 years we offer

200,000 products predominately generic, made of 50 manufacturing facilities capable of producing 80 billion doses and we need to do more. we will invest approximately $1.2 billion in research and develop intense manufacturing, roughly $3 million a day to bring affordable access to many more complex products such as insulin. our business is predicated on high volumes of hundreds of products. in the us alone we offer a portfolio of 635 products which translated last year to 21 billion doses available to patients, average price of $.25. over the last decade mylan's medicines reduced us healthcare costs by $180 billion. this is an epipen. it may look simple but it is

quite complex. in the event of anaphylaxis, severe allergic reaction, the more than 15 critical components in this device must work every time and in seconds to deliver medicine to treat life-threatening symptoms quickly and without fail. many times self administered by the person in the state of anaphylaxis. before mylan acquired the company that owned epipen in 2007 fewer than 1 million of the 43 million people at risk had access to and epinephrine auto injector. it was estimated anaphylaxis was causing 1500 deaths annually. we read the story of children dying at school because they did not have access to and epinephrine autoinjector or due to lack of education about the need was we saw this is unacceptable and largely preventable health problem. we worked diligently and invested to enhance epipen to make it more available. we tested $1 billion in these efforts over the last few years

and succeeded on many fronts, put an improved mylan epipen device on the market, we reach 80% more patients and 85% of epipen patient play less than $100, the majority less than 50. we provide access in public places starting at school and the last four years alone mylan provided 700,003 epipens across america with no strings attached. our pins were used hundreds of times including on many children who had no known allergies. i know there is concern and skepticism about the pricing of epipen and people incorrectly assume we make $600 off of each 10. simply not true. recent price increases have not yielded the revenue many assume. in the complicated world of

pharmaceutical pricing there is something known as the wholesale acquisition process. since 2014 the wholesale acquisition process increased from 401 to 608 to 51% but the net revenue to mylan after rebates and fees that we received increased from 235 to 274. the annual increase for mylan was approximately 8% a year or 60% cumulatively during this period. from that we must subtract our cost of goods which is $69 and balance $205 after subtracting epipen related cost our profit is 100, $50 per pen. in the last few weeks we confronted the epipen issue head on. our program has four parts, we announced the first ever generic of the epipen product priced at

$300, this unprecedented move is the most direct way to reduce the price for all patients. we are creating a direct shift option allowing patients to purchase the generic product directly from mylan. we increase the savings card for the product from 100 to 300, and doubled our eligibility to patients receiving free pens from 48,60097,000 to a family of four. with these changes our profits will be lower. i am honored and proud to be the ceo of mylan and spent my entire career to break down barriers to access and expand access to high-quality medicine and lower health costs. i wish we had better anticipated the magnitude of the rising financial issues for a growing minority of patients who may end a paying the costs. we never intended this. we focused on this issue and

came up with an immediate sustainable solution. going forward we will continue our leadership delivering high-quality medicine. thank you. >> i recognize myself. you never anticipated it, you raised the price. what did you think was going to happen? >> thank you, chairman. we raised the price over eight years and we raised the price, what is incorrectly assumed is the 608 is what mylan receives, we received $274 of that $608. >> here is what i don't understand. when you buy the generic version, what is the difference in the generic version? just the name? >> it will be the same product

with epinephrine auto injector. >> $600, $800, now you have a generic that will be $300. >> yes. >> if they spend $300 they get two? u - your revenue is going to go up on the direct product because you only get $275, now you get $300, correct? >> we are trying to do that in case -- we hope -- >> you are raising the price. you are going to have more revenue. >> net sales will go down dramatically. >> how can you go down? i don't know that i believe you, $274 and on a direct program you collect $300. >> that you take the cost of goods out which is $69 and then

you take out the epipen. >> you are very bright collecting $274 for two and you are going to do the generic to save people money, charge $300 your revenue goes up, how does it go down >> that will be the wholesale acquisition cost, 300, wholesale acquisition costs in half you changed is the name. this is why we don't believe you. if the price goes from 608 to 300 your collection on that is higher and you're telling me your net profit will go down? change what i'm saying is the wholesale acquisition costs, i provided this, the wholesale acquisition costs going to 300. what we will receive we are estimating at 200, it will be less, what we receive -- >> you said you will sell it

direct. >> we offer that as an option. >> how much does that cost? $300. >> we hope everybody will get it through the channels of the programs, the patient reduces the cost for everybody across all channels. >> the patient reduces the cost, explained that. >> by introducing a generic which is unprecedented for we cut the price in half. >> it is unprecedented to raise the price $500, 500%. your net revenue goes up. how can you say it goes down? >> what we receive is the 200. >> you are selling it directly for 300. >> wholesale acquisition price would be 300. >> you have got to help clarify this. this does not make sense. let me go to doug throckmorton. what is the current fda backlog

over all? what is the current backlog on drug approvals? >> currently there are 2300 new drug applications we are reviewing. that is not backlog. it is the product in the queue prior to 2012 prior to the passage, the number of products in the queue in 2012 that are unreviewed, less than 100. we have reviewed 90% of those to provide feedback to the sponsors. >> how many epinephrine products? >> can't answer that question. >> you know that number? >> i do not know that number. >> why are we having a hearing about this? >> you know that number.

here is the thing. they may tell you had the fda we never talk about this, i don't care. congress doesn't care. i want to know how many epinephrine oriented products there are right now? >> i wish i could answer that. i can get back whatever information i can to you as quickly as i can. >> we you give back the answer i asked be change i will provide whatever information i can. >> are you going to answer the question i asked? >> is. >> will the gentleman agree, give them five minutes to get answers you. i yelled back. >> how hard is it to get the answer? who knows that answer? >> i am not allowed -- simply a legal answer.

i'm not allowed to disclose confidential information in this setting. my understanding -- >> let me talk about it with staff. i don't want to slow down but it is a question we want to understand the answer to. last question, ms. bresch, this came up late in the process, surprised us. can you explain or clarify from your own vantage point role your mother played in this process? reading these articles that seem sensational i don't know what is true or not true, i'm giving you an opportunity to express your version of what is going on. >> i appreciate that the article is completely inaccurate. mylan, when we acquired this product and realize lack of awareness and access to the

product and the fact public places, let's take, a child out of school or on the playground where to go in and have every action is going to anaphylaxis and if the child didn't have a prescription in their name the school couldn't use it so these were happening because there may have been epipens or other injectors but they were not allowed to be used in children, like i said, tragically died. we felt this was unacceptable, there have only been a handful of states that started to recognize but never in auto injectors could be in a public place in the school's name, not the child's name so nurses and trained administrators could use it in the face of tragic events. we started helping the federal legislature and state legislature to quickly recognize these tragic events that can be

largely preventable and legislation began to get past to allow schools to stop epinephrine. we launched the schools program giving 700,000 over 66,000 schools with no strings attached and one of the benefits would be the other 65,000 schools will participate and receive free epipens. the burden on schools from a policy perspective training perspective, we gave amounts to various groups whether it was the national school board, national school nurses, that we could help and only helping fund them and train personnel and educate so that people could recognize and anaphylactic event and know how to administer products. my mother dedicated her life to education, been a volunteer for years and rotated one year into

the president of the national school board in 2012 and rotated out, we continued to work with these organizations to help train and educate so you may want to criticize mylan for giving free pens and having access in public places to epipen i thought it was a cheap shot to bring to my mother. >> i recognize mister cummings. >> the committee since a bipartisan quest for documents including several requests, we asked the company profits from sales of epipens each year since acquisition. you recall getting that? your company started to produce documents, we appreciate that,

we have information about your marketing with a number of other costs but one thing absent from your document is your profits. given how much you are charging for the epipen i think the american people have a right to know how much you and your fellow executives are making off of exorbitant prices for this drug so let's start with that. you have got not kinds of charts. how much profit did you make in 2015 from the sale of epipens in 2015? >> we provided as in my testimony, $50 per pen is our

profit and that is direct epipen, not taking any company allocation or anything else out of that other than direct related epipen costs. >> you have a number? how many did you sell? >> roughly over the last 12 months number of roughly 4 million. >> according to the documents you had net revenue of $912 million in 2015 for epipens after all rebates and discounts. >> we recognize the $274 per pen so our revenue is calculated on that average of what mylan received. >> you spend $97 million on marketing in 2015 alone. that is a huge amount and the

documents they sold brings you down to $850 million. do you agree? >> i am not sure. what i can confirm -- >> can you confirm what the company spends? >> $1 billion since 2008. >> the next document, $255 million in 2015 so that brings $560 million from that. you have school-based programs. the documents, how much you spend on them, how much did you spend on those in 2015 for epipens? >> i don't have the breakdown

but from 274, $69, $205 and down, $105 for epipen related costs which brings you to the $100 for two or $50 per pen. >> the fellow behind you has a different chart. maybe that will help. this is your biggest product. is that right? >> yes. >> you are telling me you don't know how much you spent on patient assistant programs last year? >> i don't have it broken out. i spent $105 would be the epipen related to those costs from marketing as well as patient programs and everything else that we spend, disease awareness, we have done quite a bit on anaphylaxis because there was such a low awareness, the

ability to educate about not only is anaphylaxis life-threatening but we now know at least 25% to 35% of the time when someone goes into anaphylaxis they have never had a known allergy before, child or adult, which drove us to get it in public places. >> we have 43 million people, customer based. how much did mylan spend on research and development directly related to epipens? >> we try to do several things that failed. >> talking about -- >> we hope within the next 12 months we have approved a new formulation that will extend the

shelf life. >> i said how much did you spend on r&d in 2015? this hearing is about epipens. i talk in my opening statement about rope a dope, that is what it feels like. you are not giving me answers. in fairness to us you knew what this hearing was about and what our concerns were. i am asking questions, you are the ceo and i would think you would know, would be on the top of your head. >> we spent $750 million this year. it is not broken down and products but i can tell you our majority of what we spend has

been on access and awareness programs, we have been working on smaller different devices due to patient feedback, we have been successful in reformulating so it will have a longer shelf life extending the time needed for resale. >> stop right there. the longer shelf life, how are we coming to that? right now it is about a year? >> 18 months. >> how are we trying to get it up? glad to hear it is 18 months. what are your researches? >> 24 months is what we are hoping for. minimum of 24 months. >> how can we know? you are spending this money, what are your researches telling you, they have an answer? >> we are looking to submitted

to the fda, we are working on it a couple years and will be with 24 months, you continue after you submit it to the fda you work on stability and an opportunity it could go longer but a minimum of 20. >> would you agree you made hundreds of millions of dollars in profit-based on sale of epipen alone? >> we have $11 billion company. i run $11 billion company and epipen is our largest product but by no means driving the entire performance of the company. >> you agree you made hundreds of millions of dollars in profits in 2015 based on the sale of epipens. i want you to produce to this

committee a breakdown for the past ten years since 2007, a list of your costs and expenses per year and profits. and the chairman is big on documents and i am too and makes it very unfair when we ask for documents. what that means is when the hearing is over, when you go back, we are then going to get the kind of information. >> i recognize the gentleman from florida for five minutes.

>> there is no generic available for competition with epipen, is there? >> there is no product to any autoinjector product for epinephrine. the generic form, authorized generic as characterized, brand-name products marketed without the brand name on its label. >> do you have under consideration attempting to produce generic competition? >> it is public knowledge companies are looking at that. >> you would have to approve them? are any being considered for approval? >> i can't comment on specific applications. >> do you have applications? >> they would have to be approved. >> how long have you had them?

>> i can't -- >> you can't tell us. we need to know which one way to bring the price down is to have competition. >> i agree with that. >> can you let the committee know for the record how many applications, you don't even have to tell us the name, how long you have been profiting >> i can't provide that information. >> that is not acceptable to come here on this subject and not have that. i understand under the affordable care act there are some exceptions to that, is that correct? under the affordable care act, epipen available? >> currently there are two products available on the market, both have been approved

as new drug product so the first is the epipen. the other is another epinephrine auto injector prescribers can write for it is available. >> how long will it take to get a generic approved? >> beginning in october on october 1st we have ten months review times for new applications. >> i want to know how long you had applications. >> i can't provide that information but i can tell you in addition to what we committed to beginning on october 1st, some products that are high product health value including first generics are eligible for priorities. >> miss bresch, in a media

interview, the implementation of the affordable care act, patients and families involved in high deductibles health insurance plans who are uninsured or pay cash pay the entire cost for their medicine. is that correct? >> yes. >> the chairman talked and staff talked about ingredients. is that correct? >> we pay $69 for the cost of the new epipen. be change is this your major profit center for the company? >> is this your major profits? >> the largest product. >> is it your major product? is it your major product?

>> it is our -- >> one of the things that concerns us, the prices are high, there isn't competition, the top 5 executives earned collective $292 million in 2011 in 2015, is that correct? is that correct? what is your salary? >> about $18 million. >> sounds like you are doing well. how does your compensation compare to peers in the industry? >> it is in the middle. >> in the middle. there are even bigger salaries.

>> yes, sir. >> where any of your payments or executive compensation packages tied to the result of epipen sales? >> no. epipen performance is a factor in overall performance. >> my time is up, i submit to the witness. >> the gentleman's time has expired. >> i appreciate this hearing. can i ask you, after the launch of criticism, any pharmaceutical in recent memory. will you reverse the increase in

price? >> by the introduction of a generic which has never been done before, and unprecedented event for a brand to cannibalize their own to $300. >> that you did in response to the criticism? that is your response to the criticism before you came to this hearing? but nothing about the brand name product. >> the way we make most immediate impact for the patient -- >> to reduce the price of the brand name product. ..patient. what we did is give immediate relief to the patients that fall into this. >> but that was your concern this may not go to the patient. so we will go immediately to -- >> yes. our concern was absolutely that everyone who needs an epipen has one. so putting a generic into the market would, we believe, be the most effective and efficient way

to make that happen. >> i asked staff, because there is some responses from you about this being only one of your products. how much -- how substantial was epipen? i was amazed by the answer. and i asked you to verify this. that mylan is 0.3% the product -- percent of the products you produce but 10% of the revenue. >> epipen is less than 10% -- a little less than 10% of our overall - >> at the pain is less than 10% of our overall -- >> only